2. Search Result
Search Result
Results for "

lower cytotoxicity

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

2

Fluorescent Dye

1

Inhibitory Antibodies

2

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W800776
    DORI

    1,2-Dioleoyl-3-dimethyl-hydroxyethylammonium bromide

    		 Liposome Others
    DORI is a cationic lipid that can deliver plasmid DNA in vitro. DORI has lower cytotoxicity and high transfection efficiency .
    DORI
  • HY-144722
    Antitubercular agent-12

    		Bacterial Infection
    Antitubercular agent-12 (Compound 2c) is an antitubercular agent (MIC = 1.439 μg/mL). Antitubercular agent-12 shows greatly lower cytotoxicity (CC50: 57.34 μg/mL) .
    Antitubercular agent-12
  • HY-143755
    Cap-dependent endonuclease-IN-9

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .
    Cap-dependent endonuclease-IN-9
  • HY-143743
    Cap-dependent endonuclease-IN-2

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .
    Cap-dependent endonuclease-IN-2
  • HY-143744
    Cap-dependent endonuclease-IN-3

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
    Cap-dependent endonuclease-IN-3
  • HY-100044
    SR 4330

    1,2,4-Benzotriazin-3-amine; Win 60109

    		 DNA/RNA Synthesis Others
    SR 4330 is a cytotoxic compound that targets hypoxic cells. The lower limits of quantification are 40 ng/mL and 20 ng/mL in mouse and human plasma .
    SR 4330
  • HY-147968
    Anticancer agent 74

    		Others Cancer
    Anticancer agent 74 is a moderate anticancer agent. Anticancer agent 74 has lower selectivity and cytotoxicity than doxorubicin to normal cell .
    Anticancer agent 74
  • HY-144298
    HDAC1-IN-4

    		Parasite HDAC Infection
    HDAC1-IN-4 (JX34) is a potent Plasmodium falciparum HDAC1 inhibitor shows antimalarial activity (IC50 < 5 nM) and lower cytotoxicity .
    HDAC1-IN-4
  • HY-147971
    Anticancer agent 75

    		Parasite Topoisomerase Infection Cancer
    Anticancer agent 75 is a potent anticancer agent. Anticancer agent 75 shows cytotoxicity and selectivity in cancer cell lines. Anticancer agent 75 shows cytotoxicity to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard. Anticancer agent 75 shows good activity of antiplasmodial .
    Anticancer agent 75
  • HY-121088
    Ceefourin 2

    		P-glycoprotein Cardiovascular Disease Others
    Ceefourin 2 is a potent and highly selective inhibitor of MRP4. Ceefourin 2 inhibits the transport of MRP4 substrates but is not selective for other ABC transporters. Ceefourin 2 shows lower cytotoxicity and higher microsomal and acid stability .
    Ceefourin 2
  • HY-107101
    (5R)-5-Hydroxytriptolide

    PG 701; LLDT-8; 5α-Hydroxytriptolide

    		 Others Inflammation/Immunology
    (5R)-5-Hydroxytriptolide is an extracted compound from Tripterygium, and shows lower cell cytotoxicity and higher immunosuppressive activity. (5R)-5-Hydroxytriptolide can be used for study of rheumatoid arthritis .
    (5R)-5-Hydroxytriptolide
  • HY-122751
    (R)-DNMDP

    		Phosphodiesterase (PDE) Cancer
    (R)-DNMDP is a potent and selective cancer cell cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, binds PDE3A directly. (R)-DNMDP has a 500-fold lower EC50 compared to the (S)-enantiomer in HeLa cell line .
    (R)-DNMDP
  • HY-115970
    Tubulin inhibitor 21

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 21 (compound 6f), a chalcone- and melatonin- based hybrid, is a potent tubulin inhibitor. Tubulin inhibitor 21 induces a remarkable cytotoxic activity toward SW480 cells (IC50=0.26 μM) with lower effect against nonmalignant cells .
    Tubulin inhibitor 21
  • HY-W158234
    N-Methylbenzo[d]oxazol-2-amine

    		Parasite Infection
    N-Methylbenzo[d]oxazol-2-amine (compound 1) is an anthelmintic activity and lower cytotoxicity against T. spiralis adult worm. N-Methylbenzo[d]oxazol-2-amine up-regulates the metabolism of purine, pyrimidine and down-regulates sphingolipid metabolism .
    N-Methylbenzo[d]oxazol-2-amine
  • HY-156593
    ROCK-IN-9

    		ROCK Cancer
    ROCK-IN-9 (Compound T345) is a ROCK inhibitor. ROCK-IN-9 shows cytotoxicity in HepG2 cell, with an IC50 of 40.8 μM. ROCK-IN-9 has good pharmacokinetic properties in mice, and shows high in vivo exposure and oral bioavailability at lower doses .
    ROCK-IN-9
  • HY-149408
    MAOA-IN-1

    		Monoamine Oxidase Cancer
    MAOA-IN-1 (compound 15) is an orally active MAOA inhibitor with cytotoxicity against prostate cancer cells. MAOA-IN-1 has Caco-2 permeability and lower CNS permeability. MAOA-IN-1 can be further used in the research of anti-cancer and anti-inflammatory indications .
    MAOA-IN-1
  • HY-143747
    Cap-dependent endonuclease-IN-5

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .
    Cap-dependent endonuclease-IN-5
  • HY-D0300
    Leucomalachite green
    1 Publications Verification

    		 Biochemical Assay Reagents Others
    Leucomalachite green is the major reduced metabolite of malachite green (MG) and has lower cytotoxicity (such as HEp-2 and Caco-2) than malachite green. Leucomalachite green may be involved in interfering with cell metabolism or redox balance and can be used to evaluate its potential harm to human cells as a food contaminant .
    Leucomalachite green
  • HY-176058
    HDAC6-IN-57

    		HDAC Cancer
    HDAC6-IN-57 (compound 9c) is an HDAC6 inhibitor with an IC50 value of 7 nM. HDAC6-IN-57 inhibits 60 cancer cell lines with a mean GI50 of 2.64 μM while exhibiting significantly lower cytotoxicity towards non-tumor cell lines .
    HDAC6-IN-57
  • HY-147505
    Antitubercular agent-21

    		Bacterial Fungal Infection
    Antitubercular agent-21 (Compound 15) is an antitubercular agent with an MIC of o.4 µg/mL against M. tuberculosis H37Rv. Antitubercular agent-21 exhibits lower activity against other microorganism such as bacteria gram-positive, gram-negative or fungi. Antitubercular agent-21 shows low cytotoxicity .
    Antitubercular agent-21
  • HY-125374
    Larotaxel

    XRP9881

    		 Apoptosis Cancer
    Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel .
    Larotaxel
  • HY-173403
    TrxR-IN-8

    		TrxR Reactive Oxygen Species (ROS) Apoptosis Cancer
    TrxR-IN-8 (Compound 6f) is a selective TrxR inhibitor (IC50: 10.2 μM). TrxR-IN-8 induces apoptosis through oxidative stress by stimulating the production of reactive oxygen species (ROS), reducing intracellular thiols, and lowering the glutathione/glutathione ratio. TrxR-IN-8 exhibits significant cytotoxicity against non-small cell lung cancer (NSCLC) cells .
    TrxR-IN-8
  • HY-D0300S1
    Leucomalachite green-d6

    		Isotope-Labeled Compounds Biochemical Assay Reagents Others
    Leucomalachite green-d6 is the deuterated derivative of Leucomalachite green (HY-D0300). Leucomalachite green is the major reduced metabolite of malachite green (MG) and has lower cytotoxicity (such as HEp-2 and Caco-2) than malachite green. Leucomalachite green may be involved in interfering with cell metabolism or redox balance and can be used to evaluate its potential harm to human cells as a food contaminant .
    Leucomalachite green-d6
  • HY-145734A
    AMXI-5001 hydrochloride

    		Microtubule/Tubulin Cancer
    AMXI-5001 hydrochloride is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 hydrochloride exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 hydrochloride induces complete regression of established tumors, including exceedingly large tumors .
    AMXI-5001 hydrochloride
  • HY-145734
    AMXI-5001

    		Microtubule/Tubulin Cancer
    AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors .
    AMXI-5001
  • HY-D0300S
    Leucomalachite green-d5

    		Isotope-Labeled Compounds Biochemical Assay Reagents Others
    Leucomalachite green-d5 is the deuterated derivative of Leucomalachite green (HY-D0300). Leucomalachite green is the major reduced metabolite of malachite green (MG) and has lower cytotoxicity (such as HEp-2 and Caco-2) than malachite green. Leucomalachite green may be involved in interfering with cell metabolism or redox balance and can be used to evaluate its potential harm to human cells as a food contaminant .
    Leucomalachite green-d5
  • HY-170572
    PB01

    		Dipeptidyl Peptidase Reactive Oxygen Species (ROS) Metabolic Disease
    PB01 is a DPP-4 inhibitor with an IC50 of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes .
    PB01
  • HY-D0300R
    Leucomalachite green (Standard)

    		Biochemical Assay Reagents Others
    Leucomalachite green (Standard) is the analytical standard of Leucomalachite green (HY-D0300). This product is intended for research and analytical applications. Leucomalachite green is the major reduced metabolite of malachite green (MG) and has lower cytotoxicity (such as HEp-2 and Caco-2) than malachite green. Leucomalachite green may be involved in interfering with cell metabolism or redox balance and can be used to evaluate its potential harm to human cells as a food contaminant .
    Leucomalachite green (Standard)
  • HY-143757
    Cap-dependent endonuclease-IN-10

    		Influenza Virus Infection
    Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .
    Cap-dependent endonuclease-IN-10
  • HY-162829
    hURAT1 inhibitor 1

    		URAT1 GLUT Metabolic Disease
    hURAT1 inhibitor 1 (compound 27b) is an isomarine-based, orally active dual hURAT1/GLUT9 inhibitor with IC50s of 0.16 μM and 4.47 μM, respectively, and has anti-hyperuricemia effects. hURAT1 inhibitor 1 showed significant uric acid-lowering activity in a hyperuricemia mouse model (10 mg/kg dose). hURAT1 inhibitor 1 had no significant in vitro cytotoxicity or in vivo hepatotoxicity and showed good PK characteristics .
    hURAT1 inhibitor 1
  • HY-P99431
    KY-1044

    Alomfilimab; SAR 445256

    		 CD28 Inflammation/Immunology Cancer
    KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
    KY-1044
  • HY-154968
    RSV L-protein-IN-5

    		RSV Infection
    RSV L-protein-IN-5 (compound E) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.1 μM). RSV L-protein-IN-5 inhibits Polymerase (IC50=0.66 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-5 shows moderate cytotoxicity (CC50=10.7 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
    RSV L-protein-IN-5
  • HY-115574
    RSV L-protein-IN-1

    		RSV Infection
    RSV L-protein-IN-1 (compound D) is a potent inhibitor of Respiratory syncytial virus (RSV) (EC50=0.021 μM). RSV L-protein-IN-1 inhibits Polymerase (IC50=0.089 μM)，and blocks RSV mRNA synthesis by inhibiting guanylation of viral transcripts. RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM，HEp-2)，also exhibits activity and lowers virus titers in mouse models of RSV infection .
    RSV L-protein-IN-1
  • HY-159921
    Tubulin Polymerization-IN-1 prodrug

    		Microtubule/Tubulin Cancer
    Tubulin Polymerization-IN-1 prodrug (Compound 2b) is a palladium (Pd)-mediated tubulin polymerization inhibitor prodrug. Developed based on colchicine binding site inhibitors (CBSIs), it reduces toxicity and enhances targeted release properties. Compared to the parent compound, Tubulin Polymerization-IN-1 prodrug exhibited 68.3-fold lower cytotoxicity, which can be restored in situ in the presence of Pd resin. Mechanistic studies showed that its anticancer activity is consistent with CBSIs. In vivo, Tubulin Polymerization-IN-1 prodrug significantly inhibited tumor growth (63.2%) when activated by Pd resin. It holds promise for research in the field of anticancer therapy .
    Tubulin Polymerization-IN-1 prodrug
  • HY-133531
    PDD00017272

    		Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    PDD00017272 is an inhibitor of poly(ADP-ribose) glycohydrolase (PARG) (EC50=4.8 nM) and an activator of PARP1/2. PDD00017272 inhibits its activity of hydrolyzing poly(ADP-ribose) (pADPr), resulting in the accumulation of pADPr on chromatin, interfering with DNA damage repair and replication processes, and inducing PARP1/2-dependent cytotoxicity. PDD00017272 can be used in cancer models with DNA repair defects (such as BRCA mutations) or resistance to PARP inhibitors. PDD00017272 has a PARG expression level-correlated inhibitory potency with EC50 of 9.2 nM (PARG cells), the tumor cells with lower PARG expression are more sensitive .
    PDD00017272
  • HY-116504
    WB-308

    		EGFR Akt ERK Apoptosis Cancer
    WB-308 is a novel small molecule that was identified as an inhibitor of EGFR by an in vitro EGFR kinase activity system. WB-308 was able to reduce the proliferation and clonogenicity of NSCLC cells, causing G2/M phase arrest and apoptosis. In addition, WB-308 inhibited tumor growth in two in vivo animal models (lung orthotopic transplantation model and patient-derived clonal mouse model). WB-308 impaired the phosphorylation of EGFR, AKT, and ERK1/2 proteins. Compared with Gefitinib, WB-308 had lower cytotoxicity. This study showed that WB-308 is a new EGFR-TKI that may be considered as an alternative to Gefitinib in the clinical treatment of NSCLC.
    WB-308
  • HY-145858
    Chalcones A-N-5

    		Ferroptosis Cancer
    Chalcones A-N-5 is a trihydroxy chalcone derivative compound. Chalcones A-N-5 doesn’t show cytotoxicity at the concentration lower than 100 µM (with IC50 > 1 mM), but has a significant effect on promoting cell proliferation. Chalcones A-N-5 potentially promotes neuronal cell growth in the damaged brain tissue. Chalcones A-N-5 also inhibits ferroptosis induced by RSL or erastin and reduces the lipid peroxidation levels induced by Aβ1-42 protein aggregation. Chalcones A-N-5 is a promising molecular skeleton candidate for further development of lead compound for in vivo test to research AD .
    Chalcones A-N-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: